Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?

Citation data:

Pharmacoepidemiology and drug safety, ISSN: 1099-1557, Vol: 21, Issue: 5, Page: 524-34

Publication Year:
2012
Usage 51
Abstract Views 51
Captures 6
Exports-Saves 6
Citations 16
Citation Indexes 16
Repository URL:
https://works.bepress.com/leslie_harrold/46; https://escholarship.umassmed.edu/meyers_pp/542; http://kpresearchpublications.kp.org/handle/kp/8246
PMID:
22411435
DOI:
10.1002/pds.3238
PMCID:
PMC3330193
Author(s):
Toh, Sengwee; Li, Lingling; Harrold, Leslie R.; Bayliss, Elizabeth A.; Curtis, Jeffrey R.; Liu, Liyan; Chen, Lang; Grijalva, Carlos G.; Herrinton, Lisa J.
Publisher(s):
Wiley-Blackwell
Tags:
Medicine; Antibodies, Monoclonal; Autoimmune Diseases; Immunoglobulin G; Infection; Health Services Research; Primary Care
article description
Infliximab, a chimeric monoclonal anti-TNFα antibody, has been found to increase the risk of serious infections compared with the TNF receptor fusion protein etanercept in some studies. It is unclear whether the risk varies by patient characteristics. We conducted a study to address this question.